Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Darolutamide is structurally different from the 2 FDA-approved antiandrogen agents apalutamide (Erleada) and enzalutamide (Xtandi), Concepcion says. The hypothesis among researchers was that this slight difference in molecular construct would give darolutamide an advantage in terms of central nervous system toxicity. At the 2019 Genitourinary Cancers Symposium, researchers reported that darolutamide not only delayed time to metastases versus placebo, but it also had a more favorable toxicity profile. This was specific to fatigue, which is significant under therapy with enzalutamide or apalutamidesomewhere on the order of 20% to 30%, Concepcion notes.

Videos

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

Assessing the Role of Darolutamide in CRPC

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.

There remains a need for a way for physicians to determine which prostate cancer patients need to be biopsied and if the detected tumor is high-grade.

An early study of about 1000 patients analyzed the 4Kscore test in this space.

The 4Kscore test, with certain limits, may be able to predict higher-grade cancers. This test could reduce the number of biopsies without missing a significant number of high-grade tumors.

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.


Raoul S. Concepcion, MD, FACS | Authors

Articles

Assessing the Role of Darolutamide in CRPC

The 4Kscore Test as a Predictor of High-Grade Prostate Cancer